In mice, oral vanadyl sulfate (VS), a mineral supplement, killed senescent cells, eased aging phenotypes and age-related disorders, and extended lifespan in males. Senescent cells showed globally reduced cysteine reactivity yet heightened endoplasmic reticulum proteostasis machinery, a state tied to glutathione disulfide (GSSG) buildup after glutathione reductase downregulation. VS locked reactive cysteines and drove disulfide bond formation, causing protein misfolding, aggregation and cell death selectively in senescent cells.
This evidence comes entirely from animals and cell models, so nobody should read it as a reason to start taking vanadyl sulfate. Its main contribution is mechanistic: it identifies a redox-proteostasis weakness that distinguishes senescent from healthy cells, offering a fresh senolytic target beyond the well-known BCL-2 inhibitor and dasatinib-quercetin approaches. The lifespan benefit appeared only in males, a recurring pattern in mouse longevity work (rapamycin and others show sex-dependent effects) that tempers enthusiasm. Vanadium compounds were tested for diabetes decades ago and abandoned in part over gastrointestinal effects and toxicity concerns at sustained doses, and the safety margin for long-term dosing in humans is unknown. Over-the-counter vanadyl sulfate is sold to bodybuilders, so the practical risk is people extrapolating from this paper. Senolytics overall remain unproven for extending human healthspan. I'd call this a promising, high-quality preclinical finding that opens a mechanistic door but sits several translational steps from any human recommendation. Replication in other mouse strains and both sexes would be the next test.